2 citations
,
May 2024 in “Journal of science and medicine in sport” This position statement reviews the role of exercise professionals in managing PCOS and provides recommendations for physical activity, but it reports no new clinical findings.
This review highlights that iron deficiency is a significant yet often overlooked contributor to the development of immune-mediated inflammatory skin diseases, suggesting that iron dysregulation may drive inflammation and metabolic imbalances in conditions like psoriasis and atopic dermatitis.
17 citations
,
October 2023 in “Molecules” In laboratory and artificial skin model experiments, this study found that plant-derived PDRN from Korean ginseng effectively promoted skin cell regeneration and strengthened the skin barrier, suggesting a sustainable alternative to animal-derived PDRN.
This scoping review identifies various pharmacological agents and five key mechanistic strategies being studied in vivo to mitigate multi-organ toxicity caused by cytarabine, with apraglutide and N-acetylcysteine highlighted as promising candidates for clinical application.
January 2025 in “Pharmaceuticals” This review discusses the potential of peptide-based hydrogels as biomaterials for treating chronic wounds and reports no new clinical findings.
50 citations
,
May 2018 in “International journal of cardiology” This study found associations between genetic predictors of increased testosterone and cardiovascular risk factors, but the implications for testosterone supplementation are unclear due to uncertainties in genetic variant functions.
May 2026 in “Pharmaceuticals” This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.
46 citations
,
April 2021 in “International Journal of Molecular Sciences” This review discusses the potential of curcumin and its formulations to mitigate neuropathic and postoperative pain, highlighting positive outcomes in preclinical and clinical studies but noting the need for further clinical research.
May 2024 in “Molecules/Molecules online/Molecules annual” This narrative review reports that well-selected plant extracts and their active compounds may improve hair health by promoting hair growth and preventing hair loss, potentially aiding in developing targeted therapies for alopecia.
1 citations
,
January 2024 in “International journal of molecular sciences” This review outlines that in women with PCOS, microRNAs (miRNAs) are abnormally expressed in various tissues compared to those without the condition, suggesting these miRNAs as potential biomarkers and therapeutic targets, given their role in pathways critical to PCOS and potential interactions affecting reproductive outcomes.
June 2023 in “Pharmaceuticals” This review reports that sex-related differences in pharmacological response have been observed in SARS-CoV-2 infection, dyslipidemia, and diabetes mellitus, with implications for treatment strategies; for example, men may respond better to genomic vaccines for SARS-CoV-2, while women may benefit more from certain antiviral medications.
November 2025 in “Cosmetics” This study found that of the many ingredients advertised in shampoos as effective against hair loss, only caffeine, adenosine, placental proteins, and melatonin have limited clinical evidence supporting their efficacy, with most claimed active ingredients lacking any trial-based validation.
March 2008 in “The Knowledge Bank (The Ohio State University)” This study found that AR-007 degrades faster and has a stronger association with hsp70 than AR-014, suggesting it is less stable when bound to the androgen receptor.
January 2014 in “theses.fr (ABES)” In this research, Sertoli cell line model ST38c demonstrated that the androgen receptor regulates hormone pathways through specific coregulators, suggesting roles for SRC-2 and HBO1 in testicular development and androgen responsiveness.
2 citations
,
December 2013 in “Cancer research” In this study, GTx-027, a selective androgen receptor modulator, significantly inhibited tumor growth in certain breast cancer models and showed good tolerance in a Phase II trial with postmenopausal women.
56 citations
,
November 2007 in “Molecular and cellular endocrinology” This study identified enzymes responsible for regulating androgen action in the human prostate, suggesting that inhibiting AKR1C2 or RL-HSD may have therapeutic potential in androgen insufficiency or benign prostatic hyperplasia, respectively.
36 citations
,
October 2009 in “Journal of biological chemistry/The Journal of biological chemistry” This study reports that TFM-4AS-1, a selective androgen receptor modulator, promoted bone and muscle growth with reduced effects on reproductive organs in ovariectomized rats.
89 citations
,
August 2013 in “PloS one” This study used the "ARE-Luc" mouse model to visualize androgen receptor activity across various tissues in both male and female mice, highlighting the direct action of androgens outside reproductive organs.
13 citations
,
April 2022 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” This comprehensive literature review highlighted that lichen planopilaris and frontal fibrosing alopecia, both primary scarring alopecias, are diagnosed via scalp biopsy, with no standardized treatments available, necessitating individualized therapeutic approaches based on patient characteristics.
2 citations
,
December 2022 in “Journal of Clinical Medicine” This review suggests that, among non-hormonal treatments for menstrual irregularities in adolescents with PCOS, metformin is the most effective and cost-efficient option, particularly in overweight adolescent girls.
2 citations
,
January 2018 in “PubMed” This case report describes a 45-year-old man with a pituitary macroadenoma whose symptoms and tumor size improved significantly after one month of treatment with cabergoline.
1 citations
,
January 2022 in “Journal of Biosciences and Medicines” This review discusses the roles of androgens and androgen receptor in skin diseases like acne and hirsutism, and highlights the promise of antiandrogen drugs, reporting no new clinical findings.
May 2026 in “Journal of Medicinal Chemistry” In this study, the authors developed a novel PROTAC named dAR-6–1, which demonstrated superior hair regeneration in an AGA mouse model compared to minoxidil, highlighting its promise as a therapy due to potent AR degradation and excellent skin permeability.
50 citations
,
April 2010 in “Biology direct” This study's model suggests that low androgen levels can increase selection for prostate cancer phenotypes resistant to hormonal therapy, potentially leading to more aggressive forms of cancer.
February 2024 in “Cancers” This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.
140 citations
,
February 2014 in “Neuron” This study found that the opioid system, particularly via the delta opioid receptor, broadly regulates cutaneous mechanosensation, including touch, and suggests targeting this receptor could alleviate injury-induced mechanical hypersensitivity.
55 citations
,
May 2019 in “Journal of Endocrinology” This review summarizes research on androgens' roles in female reproductive function, noting their impact on IVF outcomes and the development of PCOS, and highlights the need for mechanism-based therapies.
51 citations
,
August 2012 in “Differentiation” This study found that penile and clitoral differentiation in mice is influenced by androgen exposure, with penile features developing postnatally requiring prenatal and ongoing androgen presence.
36 citations
,
June 2014 in “PLOS ONE” This study found that men with persistent sexual side effects after using finasteride for androgenetic alopecia had higher androgen receptor expression in certain tissues compared to those who never used the drug.
21 citations
,
April 2016 in “International Journal of Oncology” This study found that treatment with the GnRH agonist Triptorelin significantly decreased invasion and expression of S100A4 and CYR61 in certain breast cancer cells, suggesting a potential role in slowing cancer progression.